|
Teicoplanin, a glycopeptide antibiotic, has potential for use as an alternative to vancomycin in the treatment of gram-positive bacterial infections. However, unlike vancomycin, there is a lack of study on teicoplanin’’s efficacy and safety and the guideline for its use is not available, yet. The objective of this study was to investigate and evaluate the pattern of teicoplanin usage in a university hospital. A retrospective study was performed on 72 adult patients, who took teicoplanin for 3 continuous days at D. University hospital from 1 January 1999 to 30 June 2000. The microorganisms treated with teicoplanin were methicillin-resistant Staphylocorcus aureus (69%), coagulase-negative Staphylococci (12%), Enterococcus (4%), vancomycin-resistant Enterococci (2%), Streptococci (2%), and Bacillus (1%). The types of infection treated with teicoplanin were surgical wound infection (58%), lower respiratory infection (11%), bactremia (7%), urinary tract infection (5%), pleural fluid infection (4%), and peritoneal fluid infection (2%). The mean duration of teicoplanin usage was 16.5 days and teicoplanin was used with 1.4 other antibiotics, which were aminoglycosides (isepamicin, amikacin, netilmicin, astromicin) or quinolones (ciprofloxacin, tosufloxacin) or the third generation cephalosporin (ceftazidime). Only 24 cases (28.6%) met with the criteria for the justification of use, and the rest of 60 cases (71.4%) did not meet the criteria. In 84 cases (100%), blood culture tests were performed prior to the initial dose of teicoplanin. In 83 cases (99%), serum creatinine were conducted before the initial doses. In 45 cases (53.6%), serum creatinine was monitored at least twice weekly. In 55 cases (65.5%), WBC was tested at least twice weekly. In 84 cases (100%), body temperature was monitored at least once per nursing shift. In 15 cases out of 56 cases, maximum temperature decreased at least 1 degree within 3 days of teicoplanin use. In 15 case out of 35 cases, WBC values were within the normal range after treatment. In 23 cases (27.4%), dosage regimen was appropriate. Drug-related adverse effects were reported in 13 cases. Nephrotoxicity (progressively increasing SCr. or sustained SCr increase of geq0.5 mg/dl from baseline) was noted in five cases. Neutropenia (absolute neutrophil count <1,500 cells/mm^3) was noted in one case and eosinophilia (total eosinophil count >350 cells/mm^3) was noted in seven cases. A more strict control on use of teicoplanin is required, considering that teicoplanin is categorized as one of restricted antibiotics.
|